Ardelyx, Inc.
ARDX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.08
KIRA · Stoqly’s AI analyst, in plain words
- Ardelyx, Inc. had $407M of revenue in fiscal 2025, up 22.1% on the year before. Over five years, revenue changed +121.9% a year on average.
- Its operating margin was −10.1%, down 1.7 pts: of every 100 in sales, about −10 is left after running the business.
- Ardelyx, Inc. lost $61.6M in fiscal 2025.
- Free cash flow was −$44.0M in fiscal 2025, −10.8% of revenue.
- Ardelyx, Inc. has $61.9M more cash than debt.
Market cap
$764M
P/E
—
Revenue
$407M
Net income
−$61.6M
Free cash flow
−$44.0M
Operating margin
−10.1%
Ardelyx, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+22.1%
Yes. Sales grew 22.1% last year.
Does it make a profit?
−15.1%
No. It lost money last year.
Does profit turn into cash?
−10.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ardelyx, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- ARDELYX, INC.
- CIK
- 0001437402
Ardelyx, Inc. · ARDX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.1M | $52.2M | $124M | $334M | $407M |
| Revenue growth | 33.4% | 416.6% | 138.6% | 168.1% | 22.1% |
| Gross margin | 90.1% | 92.1% | 85.7% | 84.8% | 90.3% |
| Operating margin | −1,528.6% | −122.2% | −50.8% | −8.4% | −10.1% |
| Net income | −$158M | −$67.2M | −$66.1M | −$39.1M | −$61.6M |
| Net margin | −1,566.5% | −128.9% | −53.1% | −11.7% | −15.1% |
| Diluted EPS | −$1.52 | −$0.42 | −$0.30 | −$0.17 | −$0.26 |
| Cash | |||||
| Cash from operations | −$153M | −$70.0M | −$89.7M | −$44.8M | −$42.5M |
| Capital expenditure | $1.9M | $0.1M | $0.3M | $1.0M | $1.5M |
| Free cash flow | −$154M | −$70.1M | −$90.1M | −$45.8M | −$44.0M |
| FCF margin | −1,529.3% | −134.4% | −72.4% | −13.7% | −10.8% |
| Share count change | 16.3% | 52.3% | 38.2% | 7.3% | 2.5% |
| Debt and strength | |||||
| Cash and short-term investments | $117M | $124M | $184M | $250M | $265M |
| Debt incl. finance leases | $32.3M | $26.7M | $49.8M | $151M | $203M |
| Shareholders' equity | $82.6M | $98.3M | $167M | $173M | $167M |
| Current ratio | 2.5x | 2.3x | 4.9x | 4.6x | 4.3x |
| Interest coverage | −34.3x | −18.8x | −12.8x | −2.1x | −2.0x |
| Returns and quality | |||||
| Return on capital | — | −4,453.5% | −154.6% | −29.8% | −30.8% |
| Return on equity | −151.6% | −74.3% | −49.8% | −23.0% | −36.2% |
| Return on tangible equity | −191.4% | −68.3% | −39.6% | −22.6% | −36.9% |
| Piotroski F-score | 3 | 4 | 3 | 2 | 3 |
| Altman Z'' | −17.6 | −11.5 | −5.0 | −2.2 | −2.3 |
Insiders bought, 12 months
$1.9M
1 insider
Insiders sold, 12 months
$4.3M
9 insiders
Of sales under plans
54%
$2.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ardelyx, Inc. · ARDX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.08 a share, the company is worth $764M.
Source: SEC EDGAR XBRL filings (CIK 0001437402). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.